IBM, Broad to use AI to improve CV genetic risk prediction

The Broad Institute of MIT and Harvard and the IBM Watson Health business of IBM Corp. (NYSE:IBM) have teamed up to develop artificial intelligence algorithms to improve the predictive power of polygenic scoring of cardiovascular disease risk. The AI models will integrate and analyze genetic risk factors within a patient's genome, electronic health

Read the full 534 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE